CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 106 enrolled
Drug / intervention
Dimethandrolone Undecanoate +1 moredrug
Likely dose
Dimethandrolone Undecanoate 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02927210
NCT02927210Phase 1Completed

Injectable DMAU for Male Contraception: Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Single IM or SC DMAU Injection Dose Escalation Study in Healthy Male Volunteers

Kimberly Myer·interventional·Posted Oct 6, 2016·Updated Oct 31, 2025

In Brief

A Phase 1 clinical trial evaluating Dimethandrolone Undecanoate and Placebo for Healthy Men and Male Contraception. Completed, enrolled 106 participants across 2 sites.

Detailed Summary

This is a Phase I multicenter, double-blind, single dose, dose-ranging study, in healthy men to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of Dimethandrolone Undecanoate (DMAU) administered as an intramuscular or subcutaneous injection.

Study Details

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 6, 2016
Enrollment StartFeb 15, 2017
Primary CompletionNov 7, 2024
Study CompletionApr 29, 2025
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 9.7 years ago

Interventions

Dimethandrolone Undecanoatedrug

Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).

Placebodrug

Placebo injections that look like the DMAU injections but with no active ingredients